To the best of our knowledge, the present study is the first large-sample size study to comprehensively investigate the correlation between concomitant mutations and the efficacy of ALK inhibitors according to next-generation sequencing data in patients with ALK rearrangement NSCLC. Here, ALK is linked to non-small cell lung carcinoma.